Reimbursed Care Access in Ukraine

Currently classified as a psychotropic substance prohibited for circulation and not authorized for medical use outside of approved clinical research; possession and trafficking are criminalized under Ukrainian drug laws. Standard enforcement and criminal penalties for importation, possession above personal-use thresholds, and trafficking have been reported in Ukrainian media and drug‑control communications. # #

Currently classified as a strictly controlled psychotropic substance under national scheduling with no authorized routine medical use outside of approved clinical research; importation, possession and trafficking are criminal offenses. No national regulatory approval or public reimbursement for MDMA-assisted therapy has been published; advocacy and discussion of PAT exist but have not led to MDMA approval for clinical practice. #

Esketamine (Spravato) does not appear to have a publicly reported national marketing authorization or a national reimbursement listing in Ukraine as of available sources; no official Ukraine Ministry of Health approval record for esketamine retail marketing has been identified in policy summaries. Ketamine (racemate) is authorized in Ukraine as an anaesthetic and has been used off‑label in at least one Ukrainian hospital for ketamine‑based psychotherapeutic protocols under institutional licences and protocols, but this practice has been described as operating under private/ hospital arrangements rather than as a covered public benefit. Consequently, esketamine—if imported or used—would almost certainly be an unregistered/off‑label product requiring special import/compassionate‑use procedures and would not be reimbursed by standard public insurance without explicit ministry listing. # #

Ketamine is an authorised medicinal product in Ukraine for anaesthesia and is used clinically; therapeutic/off‑label use for psychiatric indications (including ketamine‑assisted psychotherapy) has been reported at least at one hospital operating under Ministry of Health and State Drug Control licensing and local clinical protocols. This off‑label administration is provided within hospital/private clinic frameworks, based on individual patient consent and local protocols, and is not described in sources as broadly reimbursed by national public health insurance—access is therefore effectively private or institutionally arranged. The Ministry of Health, State Service for Medications and Drug Control, and hospital licensing requirements control such use. Clinical‑trial grade or officially regulated psychiatric ketamine programmes remain very limited. # #

Currently classified as a prohibited psychotropic substance with active enforcement against importation and circulation; criminal seizures and prosecutions for attempted importation/trafficking have been reported. There is no authorization for medical use or routine clinical access outside of exceptional and tightly controlled research permissions (none widely reported as active). #

Currently classified within Ukraine's controlled psychotropic substances framework with no authorized medical use outside approved clinical research; importation, possession and trafficking are criminal offenses. No national approval, reimbursement pathway, or established clinical programme for 5‑MeO‑DMT has been identified in public sources. #

Currently classified as a controlled/psychotropic substance with no authorized medical use and no public reimbursement; use and importation would be prohibited outside of any narrowly authorized research framework (no active, widely reported approved clinical programmes). Reports and policy summaries treat ibogaine as part of the broader group of psychedelics currently not permitted for routine medical practice. #

The active constituents (DMT and related tryptamines) are controlled substances in Ukraine and ayahuasca preparations containing those constituents are prohibited for circulation and not authorized for medical use outside approved clinical research. Enforcement actions related to importation of DMT‑containing materials have been reported. #

Mescaline and mescaline‑containing cacti preparations are controlled under Ukrainian psychotropic/narcotic laws; there is no authorised medical programme or reimbursement for mescaline in Ukraine and possession/trafficking are subject to criminal sanction. No public medical approvals or clinical programmes have been identified. #

Members of the 2C family are treated as controlled psychotropic compounds under Ukraine's drug control framework and are not authorized for medical use outside of approved research; trafficking, possession and importation are prosecutable offences. No medical approvals or reimbursement pathways exist for 2C‑series substances. #